Objective: To explore whether levetiracetam and valproic acid are associated with insulin
resistance and to determine their effects on glucose and insulin levels among
different age groups.
Methods: Demographic data were
collected for epileptic patients from different age groups with a normal body
mass index and no chronic endocrine disease who were on levetiracetam or
valproic acid therapy. In addition to routine laboratory tests, fasting insulin
level was checked and Homeostatic Model Assessment for insulin
resistance calculated for all patients. Based on these
measurements, the effects of levetiracetam and valproic acid on laboratory
parameters were compared statistically.
Results: A total of 61 patients (30
males, 31 females) diagnosed with epilepsy were included in the study. Thirty-four
(55.7%) the patients were less than 15 years of age and the others were older.
Twenty-three (37.7%) patients were on valproic acid therapy and 38 (62.3%) patients
were receiving levetiracetam. Thirty-two (52.5%) the patients tested positive
for insulin resistance and others were insulin resistance-negative. Nine (28.1%)
patients on valproic acid treatment and 71.9% (n = 23) of patients on levetiracetam
treatment were insulin resistance-positive.
Conclusions: In the
present study, contrary to the published literature, levetiracetam was found to
be associated with further negative effects on insulin and blood glucose
metabolism compared to valproic acid. We determined that levetiracetam had a
distinct pharmacokinetic profile in pediatric patients as demonstrated by its
effects on glucose and insulin metabolism.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Original Articles |
Authors | |
Publication Date | January 4, 2019 |
Submission Date | January 23, 2018 |
Acceptance Date | February 25, 2018 |
Published in Issue | Year 2019 Volume: 5 Issue: 1 |